Last reviewed · How we verify

Topical Diclofenac gel 1% — Competitive Intelligence Brief

Topical Diclofenac gel 1% (Topical Diclofenac gel 1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Rheumatology / Pain Management.

marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2 Rheumatology / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Topical Diclofenac gel 1% (Topical Diclofenac gel 1%) — University of California, Davis. Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of application.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Topical Diclofenac gel 1% TARGET Topical Diclofenac gel 1% University of California, Davis marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2
Cytotec Misoprostol Pfizer marketed NSAID combined with prostaglandin analog Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors 1988-01-01
Bromfenac Ophthalmic Solution B Bromfenac Ophthalmic Solution B Bausch & Lomb Incorporated marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
Tinoridine HCl Tinoridine HCl Takeda marketed Non-steroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
Prolensa 0.07% Ophthalmic Solution Prolensa 0.07% Ophthalmic Solution Nicole Fram M.D. marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
aspirin and [NSAID] aspirin and [NSAID] POZEN marketed NSAID combination Cyclooxygenase (COX-1 and COX-2)
Voltaren® Gel Voltaren® Gel Glenmark Pharmaceuticals Ltd. India marketed Topical NSAID COX-1 and COX-2 enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

  1. Università degli Studi di Brescia · 4 drugs in this class
  2. Bausch & Lomb Incorporated · 4 drugs in this class
  3. Bayer · 3 drugs in this class
  4. Pfizer · 3 drugs in this class
  5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
  6. Organon and Co · 3 drugs in this class
  7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
  8. Bezmialem Vakif University · 2 drugs in this class
  9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
  10. Center For Excellence In Eye Care · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Topical Diclofenac gel 1% — Competitive Intelligence Brief. https://druglandscape.com/ci/topical-diclofenac-gel-1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: